Trials / Completed
CompletedNCT00092183
An Investigational Drug for the Prevention of Chemotherapy-Induced Nausea and Vomiting (MK-0869-071)
A Randomized, Double-Blind, Parallel-Group Study Conducted Under In-House Blinding Conditions to Determine the Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated With Moderately Emetogenic Chemotherapy
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 866 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This protocol will study an investigational drug treatment plan against standard therapy in the prevention of chemotherapy-induced nausea and vomiting in patients diagnosed with breast cancer who are to be treated with up to 4 cycles of non-cisplatin moderately emetogenic chemotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MK0869, aprepitant / Duration of Treatment: 3 days | |
| DRUG | Comparator: ondansetron / Duration of Treatment: 3 days |
Timeline
- Start date
- 2002-10-10
- Primary completion
- 2003-12-01
- Completion
- 2004-02-11
- First posted
- 2004-09-24
- Last updated
- 2017-05-05
Source: ClinicalTrials.gov record NCT00092183. Inclusion in this directory is not an endorsement.